CClinicalTrials.gg
Not yet recruitingNCT07605091Updated Jul 17, 2026

RELIANCE: Moringa in Lactation and Early Childhood

An interventional study of Moringa Leaf Powder and Carrier in Breast Feeding and Lactation, sponsored by Philip Kern. Not yet recruiting at 1 site in United States. Open to female participants aged 7 Days to 99 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-17.

Sponsored by Philip Kern · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
7 Days to 99 Years
Sex
Female
01

Study summary

This study will assess the impact of maternal moringa supplementation to mothers of breastfeeding infants on milk output, milk composition, exclusive breastfeeding duration, and maternal and child health. This will be accomplish by conducting a randomized, controlled dietary intervention study enrolling breastfeeding mothers and their newborn infants. Mothers will be randomized to receive either 10g dried moringa leaf powder in carrier vs. carrier alone, consumed daily for four months, with follow-up for 2 years.

Women must be >18 years of age, ≤ 21 days postpartum and currently lactating at the time of enrollment. Infants must be at least 37 weeks of gestational age, be healthy and are able to feed orally and consume human milk.

After randomization and enrollment, breast milk samples will be obtained at baseline, 2, 4, 6, 9 and 12 months. Serum from mothers will be collected at recruitment, 2, 4, 6,and 12 months; infant serum will be collected by capillary sample at recruitment and approximately at 2, 6, 12, and 24 months. Infant feeding weights (test weights) will be collected on sequential days at recruitment, 4, and 6 months.

Dietary recall: the foods and drinks consumed by mothers in the past month prior to each milk sample.

Other assessments will include perceptions of breastfeeding, assess complementary feeding practices. Review will be conducted of maternal and infant infections, diagnoses, and hospitalizations at the time of visit or since the last visit.

Read the detailed description

Introduction: The objective of the proposed study is to assess the impact of maternal moringa supplementation to mothers of breastfeeding infants on milk output, milk composition, exclusive breastfeeding duration, and maternal and child health. This will be accomplished by conducting a randomized, controlled, dietary intervention study enrolling 100 breastfeeding mothers and their newborn infants with four months intervention and two years follow up. The propose design is for a study of 10g dried moringa leaf powder in carrier vs. carrier alone, consumed daily for four months by breastfeeding mothers of term infants. The investigators will continue the intervention for four months and follow-up for 2 years.

Inclusion Criteria: Women must be >18 years of age; ≤ 21 days postpartum and currently lactating at the time of enrollment. Infants must be at least 36 weeks gestational age at birth, singleton birth, exclusively breastfeeding at the time of enrollment.

Exclusion Criteria: Women who report regular consumption of moringa in the last month (>1 time weekly) or are unable unwilling to lactate are ineligible to participate in this study. Infants are ineligible if born before 37 weeks of gestational age, have significant congenital disease, are unable to feed orally, or unable to consume human milk.

Overall Design: A randomized, controlled dietary intervention trial, titled The MiLC Study: Moringa in Lactation and Early Childhood.

Recruitment and Retention: Potential study participants will be identified on arrival to their first postnatal visit to the SUNY Downstate Maternal and Child Health Clinics. All eligible participants will be offered enrollment. Participants will be screened by trained research assistants and enrolled into the study with individual or caregiver informed consent and monthly check-ins. Participant follow-up will occur concurrent with pediatric monitoring visits (approximately 2, 4, 6, 9, 12, 15, 18, 24 months) for two years utilizing study staff and study equipment. Follow-up not requiring in-person visits or participants who do not arrive to their scheduled study visit will receive phone call/text communication to obtain study information and to reschedule follow-up.

Randomization: Upon enrollment, participants will be randomized to the intervention group and the control. All members of the study team will be blinded to this assignment until all primary outcomes are analyzed.

Intervention and control: Intervention and control that are validated through an acceptability trial and subsequently through the investigators pilot clinical trial. Moringa leaf powder at 10g/day was deemed acceptable by mothers previously. The most palatable combination will be utilized for the trial. The control group will receive carrier alone. Moringa at this dose and higher has been used in multiple clinical trials including the investigator's own pilot with no known adverse effects; these are summarized in the systematic review. The investigators think that the carrier alone is the best control for this study. All subjects will be consuming a palatable carrier of approximately equal calories.

Sample collection: The investigators will obtain breast milk samples (\~5ml/timepoint) at baseline, 2, 4, 6, 9 and 12 months in a light-protected manner, as retinols and carotenoids are light-sensitive. The investigators will follow protocols piloted in the prior clinical trial. Women will be asked with study staff supervision to perform expression of the whole breast standardized to the early morning. This will occur outside of direct sunlight, and milk samples will be swirled and aliquoted by study staff then stored on dry ice until transport, where they will be stored at -80C. Serum from mothers will be collected at recruitment, 2, 4, 6,and 12 months; infant serum will be collected by capillary sample at recruitment, 2, 6, 12 and 24 months. Infant hemoglobin will be assessed as per usual clinical protocol at 12 months. 24-hour pre- and post-infant feeding weights (test weights) will be collected on sequential days at recruitment, 4, and 6 months. Investigators will provide a validated scale and clear instructions on weights, and request photographic documentation of weight.

Test weights: Test weights will be performed by weights on provided digital scales in the same clothing or consistently naked before and after each feed. This will occur over a standardized 24 hour period at each collection timepoint. Mothers will record the weights in a parent diary and send photos of the weights to the study team.

Dietary recall: Investigators will review the foods and drinks consumed by mothers in the past month prior to each milk sample.

Perceptions of breastfeeding survey and additional information: At each follow-up, the investigators will do the following: • administer a short, structured questionnaire to mothers to assess their perceptions of infant satiety, adequacy of milk production, and concerns about their provision of milk to their infant.

  • assess complementary feeding practices (introduction of anything that is not prescribed medication to the infant)
  • review of maternal and infant infections, diagnoses, and hospitalizations at the time of visit or since the last visit.
02

Conditions studied

  • Breast Feeding
  • Lactation

Browse trials for

03

In context

Breast Feeding

262 studies on the registry are indexed under Breast Feeding; 112 are open to participants now.

This study's planned enrollment of 100 is close to the median of 95 across 210 interventional studies indexed under Breast Feeding.

Browse Breast Feeding studies →

Lead sponsor

Philip Kern is the lead sponsor of 9 studies on the registry; 3 are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 3 (60%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
7 Days to 99 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Inclusion criteria

  • Mothers: Inclusion criteria - >18 years of age, s/p delivery of a healthy infant, and planning breast feeding.
  • Infants: must be born at term (=37-42 weeks), singleton birth, lactating, age 7-21 days at enrollment

Exclusion criteria

Exclusion Criteria:

  • Mothers - women reporting regular consumption of moringa in the last month (>1 time weekly), unable to consume moringa or unable to complete study activities within the first two weeks.
  • Mothers - Women with a contraindication to Moringa use (blood thinners, levothyroxine, antihypertensive treatments, insulin dependency).
  • Infants - significant congenital disease, are unable to feed orally.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    Carrier and Moringa Leaf Powder

    Dietary Supplement: Moringa Leaf Powder

  • Placebo comparator
    Carrier

    Other: Carrier

Interventions

  • Dietary supplementMoringa Leaf Powder

    Participants randomized to Moringa will consume 10 grams each day of the Moringa leaf powder mixed into porridge.

  • OtherCarrier

    Participants randomized to the control will be given porridge without Moringa.

06

What researchers measure

Primary outcomes

  1. Human Milk Production (milk volume)

    Human milk production measured by 24-hour infant test-weighing to estimate daily milk volume.

    Time frame: Baseline, 2 months, 4 months, 6 months, 9 months and 12 months

  2. Duration of Exclusive Breastfeeding

    Duration of exclusive breastfeeding assessed by maternal report.

    Time frame: Up to 12 months

Secondary outcomes

  1. Maternal Serum Levels of Estradiol

    Maternal serum estradiol concentration measured from blood samples to assess hormonal changes associated with lactation following moringa supplementation compared with placebo.

    Time frame: Baseline, 2 months, 4 months, 6 months and 12 months

  2. Maternal Serum Levels of Progesterone

    Maternal serum progesterone concentration measured from blood samples to assess hormonal changes associated with lactation following moringa supplementation compared with placebo

    Time frame: Baseline, 2 months, 4 months, 6 months, and 12 months

  3. Maternal Serum Levels of Prolactin

    Maternal serum prolactin concentration measured from blood samples to assess hormonal changes associated with lactation following moringa supplementation compared with placebo

    Time frame: Baseline, 2 months, 4 months, 6 months, and 12 months

07

Study locations

1 site
  • SUNDY Downstate
    Brooklyn, New York 11203, United States
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07605091
Lead sponsor
Philip Kern
Responsible party
Philip Kern (Professor, University of Kentucky) — Sponsor-investigator
First posted
May 22, 2026
Start date
Nov 2026 (estimated)
Primary completion
Sep 2029 (estimated)
Completion
Jun 2030 (estimated)
Last update
Jul 17, 2026

Study contacts

Philip Kern
Contact
pake222@uky.edu
8593232615

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion